News & Updates

In a retrospective observational study, nirmatrelvir-ritonavir trumps molnupiravir in reducing the risk of all-cause mortality at 90 days and hospitalization in COVID-19 patients with advanced kidney disease (chronic kidney disease [CKD] stage 4, ie, eGFR <30 mL/min/1.73 m2).

Potent and selective inhibition of IL-17A by izokibep produced a rapid improvement in disease activity across multiple psoriatic arthritis (PsA) domains, according to preliminary data from a phase IIb/III trial.

Upadacitinib remains effective through 5 years in patients with rheumatoid arthritis (RA) who have inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), with no new safety signals, as shown by the results of the phase III long-term extension (LTE) of SELECT-NEXT.

Findings from the phase IV INHALE-3 trial support inhaled insulin for the management of type 1 diabetes (T1D) in adults, underlining its role as an alternative insulin solution to enhance diabetes management.

The occurrence of hypertension in patients with opioid use disorder receiving methadone maintenance treatment (MMT) is associated with weight gain, reports a study.

Pemvidutide, an investigational, peptide-based GLP-1/glucagon dual receptor agonist, gains traction in the booming obesity drug market, delivering significant weight loss reductions in nondiabetic individuals with overweight or obesity in the phase II MOMENTUM trial.